EUVIMEDEUVIMED entdecken
Übersichtsarbeit

CAR‐T cell therapy in hematological malignancies: Where are we now and where are we heading for?

Aalia N Khan, Sweety Asija, Juber Pendhari, Rahul Purwar

European Journal of Haematology · 2024-01 · 112 (1) · 6-18

DOI: 10.1111/ejh.14076 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Haematology, online erschienen am 07.08.2023. Verfasst von Aalia N Khan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai, India. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Hematologic Neoplasms, Leukemia. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 80 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor T (CAR‐T) therapy has emerged as a revolutionary new pillar in cancer care, particularly in relapsed/refractory (r/r) B‐cell malignancies. Following impressive clinical outcomes in hematological malignancies, the FDA‐approved six CAR‐T cell products for indications such as lymphoma, leukemia, and myeloma. Despite the numerous advantages of CAR‐T cell treatment, several challenges exist that interfere with its therapeutic efficacy. Serious adverse effects connected with the treatment continue to be a major concern. In addition, poor persistence of therapeutics and antigen escape frequently result in tumor relapse. Exorbitant treatment cost further remains a significant barrier to its effective implementation, limiting its accessibility. This review presents progress of CAR‐T research, the key obstacles that hamper promising outcomes for patients with hematological malignancies, and a few strategies to overcome them.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenHematologic NeoplasmsLeukemiaHumansImmunotherapy, AdoptiveCell- and Tissue-Based Therapy

Stichwörter der Autor:innen

CAR-T therapyadverse eventsefficacyexorbitant costhematological malignanciesmitigation strategiestumor relapse

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai, India.

Zitieren

APA

Khan, A. N., Asija, S., Pendhari, J., & Purwar, R. (2024). CAR‐T cell therapy in hematological malignancies: Where are we now and where are we heading for?. European Journal of Haematology, 112(1), 6-18. https://doi.org/10.1111/ejh.14076

Vancouver

Khan AN, Asija S, Pendhari J, Purwar R. CAR‐T cell therapy in hematological malignancies: Where are we now and where are we heading for?. European Journal of Haematology. 2024;112(1):6-18. doi:10.1111/ejh.14076

BibTeX
@article{Khan2024,
  author = {Khan, Aalia N and Asija, Sweety and Pendhari, Juber and Purwar, Rahul},
  title = {CAR‐T cell therapy in hematological malignancies: Where are we now and where are we heading for?},
  journal = {European Journal of Haematology},
  year = {2024},
  volume = {112},
  number = {1},
  pages = {6--18},
  doi = {10.1111/ejh.14076}
}
Kostenlos starten →